Microbial L-asparaginase is an amidohydrolase enzyme with significant applications in medicine and industry. It is a critical component in the treatment of acute lymphoblastic leukemia (ALL), due to its anti-leukemic properties. Beyond its therapeutic use, the enzyme is widely used in food processing to reduce the formation of acrylamide, a known carcinogen in carbohydrate-rich foods when heated at high temperatures. The enzyme is primarily sourced from microbes, which offers benefits in terms of yield and scalability. Recent advancements in enzyme engineering and novel delivery formulations, including the use of nanotechnology, aim to improve its stability and reduce its immunogenicity. The future of L-asparaginase is being shaped by innovative approaches such as CRISPR-based engineering and synthetic biology, which promise to optimize its production and utility. This chapter provides a detailed analysis of the biosynthetic potential of several microbes, recent advances in enzyme engineering, and novel delivery formulations, with the aim of elaborating on improvements to its stability and reducing immunogenicity.